influencer on glp 1 With Stomach Paralysis Says Her Condition Isn't Due to GLP-1: 'Nothing I Did to Myself' Influencer Janelle Rohner Responds to

This move positioned Roche to compete in the metabolic disease arena, leveraging Carmots small molecule platforms to diversify beyond oncology.[3] (2023): AstraZenecas Acquisition of CinCor Pharma Though primarily targeting hypertension, AstraZenecas US$1.8 billion buyout of CinCor included a nod toward combinational potential with metabolic therapies, signaling broader interest in cardiometabolic synergies.[4] (2024, 2025): Pfizers Strategic Reassessment and Potential for Acquisitions After halting internal development of its oral GLP-1 candidate due to tolerability concerns, Pfizer has publicly stated its interest in acquiring external GLP-1 assets

- Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

Peptide Therapy : CJC-1295 is often used in peptide therapy to increase growth hormone production, enhance recovery, and support anti-aging benefits

doi: 10.1016/j.nutres.2020.04.001 26 iftciG.TunaE

Andrew Huberman: Now they have a second study